mlsanityData to 7 Oct 2026

Evolutionary Multi-Objective Design of SARS-CoV-2 Protease Inhibitor Candidates

arXiv 2005.02666 ↗First posted 6 May 2020cs.NE cs.LG q-bio.BMcited by 1

Not on the map. Why?

Abstract (arXiv)

Computational drug design based on artificial intelligence is an emerging research area. At the time of writing this paper, the world suffers from an outbreak of the coronavirus SARS-CoV-2. A promising way to stop the virus replication is via protease inhibition. We propose an evolutionary multi-objective algorithm (EMOA) to design potential protease inhibitors for SARS-CoV-2's main protease. Based on the SELFIES representation the EMOA maximizes the binding of candidate ligands to the protein using the docking tool QuickVina 2, while at the same time taking into account further objectives like drug-likeliness or the fulfillment of filter constraints. The experimental part analyzes the evolutionary process and discusses the inhibitor candidates.

Key facts. Cited by 1 paper in the map (data through 7 Oct 2026). First posted on arXiv 6 May 2020.

Builds on

No reference list yet.

Built on by

Cited by year

Citing papers per year: 2021: 1.

1 paper.